An open-label safety and efficacy study of an anti-CD20 antibody (rituximab, Rituxan) for anti-B-cell therapy in the treatment of systemic lupus erythematosus

Detalles Bibliográficos
Autores principales: Eisenberg, RA, Khan, S, Stansberry, J, Tsai, D, Kolasinski, S, Rieder, E, Kotzin, B, Looney, RJ, Strieber, C, Albert, D
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2004
Materias:
Poster Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2833537/
http://dx.doi.org/10.1186/ar1407

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2833537/
http://dx.doi.org/10.1186/ar1407

Ejemplares similares